Search results for " Humans"

showing 10 items of 2466 documents

Detection and characterization of Human caliciviruses associated with sporadic acute diarrhea in adults in Djibouti (horn of Africa).

2008

International audience; Recent advances in molecular diagnostics have allowed us to recognize Human caliciviruses (HuCVs) as important agents of acute diarrhea in industrialized countries. Their prevalence and genetic diversity in developing countries remains unknown. We report on the characterization of HuCVs among adults presenting acute diarrheas in Djibouti; 108 stool samples collected were screened by EIA, RTPCR, or cell cultures for the group A Rotaviruses, Adenoviruses, Astroviruses, and HuCVs, which were further characterized by genotyping. Among stool samples screened for HuCVs, 25.3% were positive. The other enteric viruses were less prevalent. The 11 HuCV strains sequenced reveal…

MaleAcute diarrheaMESH: CaliciviridaevirusesMESH : DiarrheaFecesfluids and secretionsGenotypeMESH : FemaleMESH: PhylogenyMESH: Caliciviridae InfectionsPhylogenyCaliciviridae Infections[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/VirologyMESH: Middle AgedMESH: Fecesvirus diseasesMiddle AgedMESH : AdultDiarrheaMESH: DiarrheaInfectious DiseasesMESH : Caliciviridae[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyDjiboutiFemalemedicine.symptomMESH : Caliciviridae InfectionsCaliciviridaeAdultDiarrheaAdolescentMESH : MaleBiology[ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/VirologyVirusVirologyMESH : AdolescentmedicineHumansMESH : Middle AgedGenotypingMESH: AdolescentGenetic diversityMESH: HumansMESH : HumansMESH : PhylogenyMESH: AdultMESH: DjiboutiMESH : FecesMolecular diagnosticsbiology.organism_classificationVirologyCaliciviridaeMESH: MaleMESH : DjiboutiParasitologyMESH: Female
researchProduct

Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards

2018

no abstract available

MaleAdministration Oral030204 cardiovascular system & hematologyBody Mass IndexOral anticoagulant drug0302 clinical medicineElderlyDrug PrescriptionOlder patientsRetrospective Studie80 and overMedicine030212 general & internal medicineStrokeRandomized Controlled Trials as TopicAged 80 and overAtrial fibrillation; Elderly; Oral anticoagulant drugs; Prescription rate; Internal MedicineAtrial fibrillationStrokeObservational Studies as TopicAtrial fibrillation Elderly Oral anticoagulant drugs Prescription rate Internal MedicineAdministrationOral anticoagulantFemaleHumanOralmedicine.medical_specialtyOral anticoagulant drugsSocio-culturaleDrug Prescriptions03 medical and health sciencesInternal medicineInternal MedicineHumansPrescription rateAgedRetrospective Studiesbusiness.industrySettore MED/09 - MEDICINA INTERNAAnticoagulantAnticoagulantsRetrospective cohort studymedicine.diseaseAtrial fibrillationAtrial fibrillation; Elderly; Oral anticoagulant drugs; Prescription rate; Administration Oral; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Body Mass Index; Drug Prescriptions; Female; Humans; Internal Medicine; Male; Observational Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Stroke; Internal MedicineObservational Studies as TopicbusinessBody mass indexAtrial fibrillation Elderly Oral anticoagulant drugs Prescription rate
researchProduct

Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention

2021

Background and Purpose: Clinical trials on stroke prevention in patients with atrial fibrillation have consistently shown clinical benefit from either warfarin or non–vitamin K antagonist oral anticoagulants (NOACs). NOAC-treated patients have consistently reported to be at lower risk for intracerebral hemorrhage (ICH) than warfarin-treated patients. The aims of this prospective, multicenter, multinational, unmatched, case-control study were (1) to investigate for risk factors that could predict ICH occurring in patients with atrial fibrillation during NOAC treatment and (2) to evaluate the role of CHA 2 DS 2 -VASc and HAS-BLED scores in the same setting. Methods: Cases were consecutive pa…

MaleAdministration Oral030204 cardiovascular system & hematologySettore MED/110302 clinical medicine80 and overrisk factorsMedicineatrial fibrillationProspective StudiesAged 80 and overatrial fibrillation; cerebral hemorrhage; logistic models; risk factors; white matter; Administration Oral; Aged; Aged 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Cerebral Hemorrhage; Female; Humans; Male; Middle Aged; Prospective Studies; Risk Factors; StrokeAtrial fibrillationMiddle AgedVitamin K antagonist3. Good healthStrokeAdministrationSettore MED/26 - NeurologiaFemaleCardiology and Cardiovascular Medicinewhite mattermedicine.drugOralmedicine.medical_specialtymedicine.drug_classSettore MED/26Lower riskAntithrombins03 medical and health sciencesInternal medicineHumanscardiovascular diseaseslogistic modelAgedAdvanced and Specialized NursingIntracerebral hemorrhagecerebral hemorrhagebusiness.industryWarfarinmedicine.diseaseClinical trialatrial fibrillation; cerebral hemorrhage; logistic models; risk factors; white matterCase-Control StudiesConcomitantHeart failureNeurology (clinical)businesslogistic models030217 neurology & neurosurgeryStroke
researchProduct

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension:A Double-Blind Placebo-controlled Clinical Trial

2020

Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.\ud \ud Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral monotherapy.\ud \ud Methods: In this event-driven, double-blind study, we randomly allocated 690 participants (1:1 ratio) with PAH to receive placebo or oral treprostinil extended-release tablets three times daily. Eligible participants were using approved oral monotherapy for over 30 days before randomization and had a 6-minute-walk dista…

MaleAdministration OralOral treprostinilCritical Care and Intensive Care MedicinePulmonary arterial hypertension[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractcombination therapyoralepoprostenol0302 clinical medicinepulmonary arterial hypertensionmiddle agedClinical endpointdouble-blind methodMESH: Double-Blind MethodFamilial Primary Pulmonary Hypertension030212 general & internal medicinehumansMESH: AgedMESH: Middle AgedEpoprostenol/analogs & derivativesadultHazard ratioMiddle Aged[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesantihypertensive agents3. Good healthagedfemaleMESH: Young Adultoral treprostinilMESH: Administration Oralyoung adultFemalePulmonary Arterial Hypertension/drug therapymedicine.drugAdultPulmonary and Respiratory MedicineMESH: Pulmonary Arterial Hypertensionmedicine.medical_specialtyRandomizationAdolescentclinical study; combination therapy; oral treprostinil; pulmonary arterial hypertension; sequential therapy; administration oral; adolescent; adult; aged; antihypertensive agents; double-blind method; epoprostenol; female; humans; male; middle aged; placebos; pulmonary arterial hypertension; young adultSequential therapyMESH: PlacebosMESH: EpoprostenolLower riskPlaceboadministrationClinical studyYoung Adult03 medical and health sciencesDouble-Blind Method[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmaleInternal medicineplacebosmedicineHumansCombination therapyAdverse effectPlacebos/therapeutic useAgedMESH: AdolescentPulmonary Vascular DiseaseMESH: Antihypertensive AgentsMESH: Humanssequential therapybusiness.industryMESH: AdultOriginal Articlesclinical studyMESH: MaleClinical trial030228 respiratory systemadolescentAntihypertensive Agents/administration & dosagebusinessMESH: FemaleTreprostinil
researchProduct

A fatal case of a paint thinner ingestion: Comparison between toxicological and histological findings

2010

Toluene and xylene are aromatic hydrocarbons commonly used as an industrial solvent for the manufacturing of pharmaceuticals, paints, and chemicals. The Occupational Safety and Health Administration has determined that toluene levels of 2000 parts per million (ppm) are considered dangerous to life and health. Several studies have examined the absorption of toluene and xylene following inhalation and oral ingestion in humans. Volatile organic compounds that are absorbed into the blood are distributed throughout the body; in particular, distribution of absorbed toluene and xylene in humans and rodents is characterized by preferential uptake in well-perfused and lipophil tissues such as the br…

MaleAdolescent2734XylenePoison controlPaint thinnerBrain EdemaHemorrhagePulmonary EdemaAbsorption (skin)XylenesEsophaguKidneyGas Chromatography-Mass SpectrometryPathology and Forensic Medicinetoluene xilene paint thinner ingestion self poisoning varnish-diluting solventsToxicologychemistry.chemical_compoundForensic ToxicologyEsophagusSettore MED/43 - Medicina LegalePaint thinner ingestionSelf poisoningIngestionHumansGastrointestinal ContentForensic PathologyLungSolid Phase MicroextractionChromatographyChemistryXyleneForensic toxicologyBrainTolueneGastrointestinal ContentsSuicideLiverSolventSolventsPaint thinner ingestion; Self poisoning; Toluene; Varnish-diluting solvents; Xylene; Adolescent; Brain; Brain Edema; Esophagus; Forensic Pathology; Forensic Toxicology; Gas Chromatography-Mass Spectrometry; Gastrointestinal Contents; Hemorrhage; Humans; Kidney; Liver; Lung; Male; Pulmonary Edema; Solid Phase Microextraction; Solvents; Toluene; Xylenes; Suicide; 2734Varnish-diluting solventGas chromatography–mass spectrometryHumanToluene
researchProduct

Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observa…

2009

We conducted a large observational study in 193 children and adolescents with allergic rhinitis due to grass or tree pollens to evaluate the safety and tolerability of an ultrarush high-dose sublingual immunotherapy (SLIT) regimen reaching a maintenance dose of 300 index of reactivity within 90 minutes.Children and adolescents aged 5 to 17 years with at least a 1-year medical history of allergic rhinitis with or without mild to moderate asthma due to tree pollens (birch, alder, hazel) or grass pollens (cocksfoot, meadow grass, rye grass, sweet vernal grass, timothy) were recruited. Standardized grass and tree pollen allergen extracts were used for ultrarush titration and subsequent coseason…

MaleAdolescentAdministration SublingualPoaceaeAllergic rhinitisTreesHumansGrasses; Trees; Ultrarush; Sublingual immunotherapy; Children; Safety; Allergic rhinitis; AsthmaGrassesChildChildrenSublingual immunotherapyAntigens Plant; Trees; Immunotherapy; Humans; Asthma; Child; Pollen; Child Preschool; Poaceae; Rhinitis Allergic Seasonal; Seasons; Adolescent; Administration Sublingual; Female; MaleUltrarushRhinitis Allergic SeasonalAntigens PlantAsthmaChild PreschoolPollenFemaleSeasonsImmunotherapySeasonSafetyTreeHuman
researchProduct

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Ita…

2021

Nonalcoholic fatty liver disease (NAFLD) is a common and emerging liver disease in adults, paralleling the epidemic of obesity and diabetes, and leading to worrisome events (hepatocellular carcinoma and end-stage liver disease). In the last years, mounting evidence added insights about epidemiology, natural history, diagnosis and lifestyle-based or drug treatment of NAFLD. In this rapidly evolving scenario, members of the Associazione Italiana per lo Studio del Fegato (AISF), the Società Italiana di Diabetologia (SID) and the Società Italiana dell'Obesità (SIO) reviewed current knowledge on NAFLD. The quality of the published evidence is graded, and practical recommendations are made follow…

MaleAdultEndocrinology Diabetes and MetabolismSettore MED/12 - GASTROENTEROLOGIAMedicine (miscellaneous)Settore MED/09GuidelineGuidelinesGuidelines NAFLD NASHNon-alcoholic Fatty Liver DiseaseMedicalNAFLDHumansObesitySocieties MedicalPatient Care TeamNutrition and DieteticsGuidelines; NAFLD; NASH; Adult; Delivery of Health Care; Humans; Obesity; Non-alcoholic Fatty Liver Disease; Sudden Infant DeathHepatologyGastroenterologyNASHDisease ManagementGuidelines; NAFLD; NASH; Adult; Delivery of Health Care; Female; Humans; Italy; Male; Patient Care Team; Societies Medical; Disease Management; Non-alcoholic Fatty Liver DiseasePsychiatry and Mental healthClinical PsychologyItalyGuidelines; NAFLD; NASHFemaleCardiology and Cardiovascular MedicineSocietiesDelivery of Health CareSudden Infant DeathHumanEating and weight disorders : EWD
researchProduct

Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial…

2022

: Background A significant proportion of individuals clinically diagnosed with familial hypercholesterolemia (FH), but without any disease-causing mutation, are likely to have polygenic hypercholesterolemia. We evaluated the distribution of a polygenic risk score, consisting of 12 low-density lipoprotein cholesterol (LDL-C)-raising variants (polygenic LDL-C risk score), in subjects with a clinical diagnosis of FH. Methods and Results Within the Lipid Transport Disorders Italian Genetic Network (LIPIGEN) study, 875 patients who were FH-mutation positive (women, 54.75%; mean age, 42.47±15.00 years) and 644 patients who were FH-mutation negative (women, 54.21%; mean age, 49.73±13.54 years) wer…

MaleAdultMultifactorial InheritanceSettore MED/09 - Medicina Internafamilial hypercholesterolemia; molecular diagnosis; polygenic risk score; Adult; Cholesterol LDL; Female; Humans; Middle Aged; Multifactorial Inheritance; Mutation; Gene Regulatory Networks; Hyperlipoproteinemia Type IIfamilial hypercholesterolemiaCholesterol LDLMiddle AgedLDLHyperlipoproteinemia Type IICholesterolmolecular diagnosispolygenic risk scoreMutationHumansFemaleGene Regulatory Networksmolecular diagnosifamilial hypercholesterolemia; molecular diagnosis; polygenic risk score
researchProduct

Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year…

2020

BackgroundLimited data exist regarding tenofovir disoproxil fumarate (TDF) safety and effectiveness in chronic hepatitis B virus-infected (CHB) patients with renal impairment (RI).AimsTo compare real-world data on renal safety and effectiveness of TDF vs entecavir (ETV) in CHB patients with moderate-to-severe RI.MethodsRetrospective, non-interventional, cohort study analysing medical records for TDF/ETV-treated CHB patients (54 European centres). Included patients experienced moderate-to-severe RI (creatinine clearance 20-60 mL/min [Cockcroft-Gault]) either before TDF/ETV initiation ('before' subgroup [baseline = treatment initiation]) or after TDF/ETV initiation ('after' subgroup [baseline…

MaleAdultmedicine.medical_specialtyGuanineTenofovirMEDLINEAntiviral AgentsVirus03 medical and health sciencesYoung Adult0302 clinical medicineHepatitis B ChronicRetrospective StudieInternal medicine80 and overHBVMedicineHumansPharmacology (medical)030212 general & internal medicineRenal InsufficiencyYoung adultAdult; Aged; Aged 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B Chronic; Humans; Male; Middle Aged; Renal Insufficiency; Retrospective Studies; Tenofovir; Treatment Outcome; Young AdultChronicTenofovirAgedRetrospective StudiesAged 80 and overAntiviral AgentHepatologybusiness.industryGastroenterologyvirus diseasesRetrospective cohort studyEntecavirHepatitis BMiddle Agedmedicine.diseaseHepatitis BTreatment OutcomeCohort030211 gastroenterology & hepatologyFemalebusinessmedicine.drugHuman
researchProduct

Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study

2011

Background: The long-term risk of neoplasia in Crohn's disease (CD) patients treated with infliximab is undefined. The aim was to assess, in a multicenter, matched-pair study, whether infliximab use in CD is associated with an increased frequency of neoplasia in the long term. Methods: A multicenter, long-term, matched-pair study was conducted in 12 referral inflammatory bowel disease (IBD) centers. An initial cohort of 808 CD patients, including 404 infliximab-treated (CD-IFX) and 404 matched CD controls never treated with infliximab (CD-C) studied from 1999 to 2004, was followed up for an additional 4 years (2004–2008). Cases and controls were matched for: sex, age (±5 years), CD site, fo…

MaleAdultmedicine.medical_specialtyTime FactorsCROHN'S DISEASECrohn’s disease infliximab cancer matched-pairInflammatory bowel diseaseGastroenterologyAntibodiesCohort StudiesGastrointestinal AgentsCrohn DiseaseInternal medicineNeoplasmsINFLIXIMABMonoclonalmedicineImmunology and AllergyHumanstherapeutic use Case-Control Studies Cohort Studies Crohn Diseaseetiology Survival Rate Time Factors Treatment OutcomeSurvival rateAgedCancer Infliximab Inflammatory bowel diseaseCrohn's diseasebusiness.industryGastroenterologyCase-control studyAntibodies MonoclonalCancerMiddle Ageddrug therapy Female Follow-Up Studies Gastrointestinal Agenttherapeutic use Humans Male Middle Aged Neoplasmmedicine.diseaseTreatment Outcome; Male; Time Factors; Survival Rate; Middle Aged; Female; Neoplasms; Gastrointestinal Agents; Humans; Cohort Studies; Follow-Up Studies; Aged; Adult; Antibodies Monoclonal; Case-Control Studies; Crohn DiseaseCANCERInfliximabSurgerySurvival RateSettore MED/18 - Chirurgia GeneraleTreatment OutcomeCase-Control StudiesCohortFemaleAdult Aged Antibodiebusinessmedicine.drugCohort studyFollow-Up Studies
researchProduct